Benjamin J. Hindson - Mar 22, 2022 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
President and Chief Scientific Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson
Stock symbol
TXG
Transactions as of
Mar 22, 2022
Transactions value $
$0
Form type
4
Date filed
3/24/2022, 05:17 PM
Previous filing
Feb 24, 2022
Next filing
May 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Award $0 +28.5K +17.76% $0.00 189K Mar 22, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (Right to Buy) Award $0 +71.2K $0.00 71.2K Mar 22, 2022 Class A Common Stock 71.2K $69.56 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2022 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2 This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2022 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

President and Chief Scientific Officer